Stem Cell Therapy in Thailand for US Patients

The FDA distinguishes minimally manipulated, homologous-use tissue products from cell products that are expanded in culture or used for a different function. Expanded mesenchymal stem cells fall into the second group and require an investigational new drug application or approved biologics licence.

The practical result is that most Americans can access expanded cell therapy only through a clinical trial. Trials have narrow inclusion criteria, so patients with osteoarthritis, autoimmune conditions or longevity goals are frequently ineligible.

Thailand's framework requires physician prescription and delivery in a licensed facility. It is not the FDA pathway and we do not present it as one: this is treatment under a different national regulator, and you should weigh that carefully.

Mexico, Panama and Costa Rica are shorter flights from most of the US, and some patients choose them for that reason alone. The questions worth asking are the same everywhere: who owns the laboratory, what release testing is performed on each batch, and which physician is accountable for the protocol.

We process cells in our own GMP-aligned, ISO 9001 laboratory rather than outsourcing, so donor screening, expansion and release testing sit under one chain of custody. Ask any clinic you are comparing for the same detail in writing.

Given the flight length, plan on nine to eleven days: two days for travel and time-zone adjustment, then assessment, treatment sessions and review.

You receive a written clinical summary for your physician at home. Remote follow-up is typically at one, three and six months, scheduled in Eastern, Central, Mountain or Pacific time.